Interim Report: Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial

@article{Bueno2021InterimRS,
  title={Interim Report: Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial},
  author={Susan M. Bueno and Katia Abarca and Pablo A. Gonz{\'a}lez and Nicol{\'a}s M. S. G{\'a}lvez and Jorge A Soto and Luisa F Duarte and B{\'a}rbara M. Schultz and Gaspar A. Pacheco and Liliana A. Gonz{\'a}lez and Yaneisi V{\'a}zquez and Mariana R{\'i}os and Felipe Melo-Gonz{\'a}lez and Daniela Rivera-P{\'e}rez and Carolina Iturriaga and Marcela Urz{\'u}a and Ang{\'e}lica Dom{\'i}nguez and Catalina A. Andrade and Roslye V. Berrios and Gisela Canedo-Marroqu{\'i}n and Camila Covi{\'a}n and Daniela Moreno-Tapia and Farides Saavedra and Omar P. Vallejos and Paulina Donato and Pilar Espinoza and Daniel Fuentes and Marcela Gonz{\'a}lez and Paula Carolina Guzm{\'a}n and Paula Mu{\~n}oz-Venturelli and Carlos M. Perez and Marcela Pot{\'i}n and {\'A}lvaro Rojas and Rodrigo Fasce and Jorge Fern{\'a}ndez and Judith Mora and Eugenio Ram{\'i}rez and Aracelly Gaete-Argel and Aar{\'o}n Oyarz{\'u}n-Arrau and Fernando Valiente-Echeverr{\'i}a and Ricardo Soto-Rifo and Daniela Weiskopf and Alessandro Sette and Gang Zeng and Weining Meng and Jos{\'e} Vicente Gonz{\'a}lez-Aramundiz and Alexis M. Kalergis},
  journal={medRxiv : the preprint server for health sciences},
  year={2021}
}
Background: The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil… 
An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile
TLDR
CoronaVac(R) is safe and immunogenic in subjects aged 3-17 years old and is thus likely to confer protection against infection caused by SARS-CoV-2 variants in this target population.
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
TLDR
The immune response before and after SARS-CoV-2 infection was analyzed in nine vaccine breakthrough cases, revealing that six of them exhibited circulating anti-S1-RBD IgG antibodies with neutralizing capacities after immunization, which showed a significant increase 2 and 4 weeks after symptoms onset.
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
TLDR
The use of CoronaVac in patients with ARD is supported, suggesting reduced but acceptable short-term immunogenicity and the trial is still ongoing to evaluate the long-term effectiveness/immunogenicity.
The Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Antibody Response in Participants Aged 65 Years and Older.
TLDR
The lower rates of antibody response were detected in participants aged 65 years and older and those with comorbidities both in this study and similar studies in current literature.
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
TLDR
None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants, and no definitive relationship could be established between vaccination administration and the occurrence of complications.
The effectiveness of inactivated SARS‐CoV‐2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older
TLDR
Lower rates of antibody response were detected in participants aged 65 years and older and those with comorbidities both in this study and similar studies in the current literature.
Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study
TLDR
CoronaVac was 42% effective in the real-world setting of extensive P.1 transmission, but significant protection was not observed until completion of the two-dose regimen, underscore the need to maintain non-pharmaceutical interventions when mass vaccination with CoronaVac is used as part of an epidemic response.
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
TLDR
Vaccination with CoronaVac was associated with a reduction in symptomatic covid-19, hospital admissions, and deaths in adults aged ≥70 years in a setting with extensive transmission of the gamma variant.
...
...

References

SHOWING 1-10 OF 11 REFERENCES
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
SARS-CoV-2 vaccines in development
TLDR
The development of vaccines against SARS-CoV-2 is reviewed, including an overview of the development process, the different types of vaccine candidate, and data from animal studies as well as phase I and II clinical trials in humans.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
TLDR
The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
TLDR
The data presented here represent the first insights into NAb responses in individuals from Chile, serving as a guide for future studies in the country.
A pneumonia outbreak associated with a new coronavirus of probable bat origin
TLDR
Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Age-specific mortality and immunity patterns of SARS-CoV-2
TLDR
The relative risk of COVID-19-associated death for younger individuals (under 65) is consistent across countries and can be used to robustly compare the underlying number of infections in each country, and the age distribution of deaths in younger age groups is very consistent across different settings.
Age-Associated Change in the Frequency of Memory CD4+ T Cells Impairs Long Term CD4+ T Cell Responses to Influenza Vaccine1
TLDR
Although the healthy elderly mount a level of CD4+ T cell responses after vaccination comparable to that observed in younger individuals, they fail to maintain or expand these responses, and this failure probably stems from the alteration in the frequency of CM and EM CD4- T cells in the elderly that is related to alteration in IL-7 levels.
...
...